Post-stroke spasticity management with botulinum toxin: assessment, targeted injection, and the neuromuscular junction blockade that relaxes overactive muscle.
Spasticity is a velocity-dependent increase in muscle tone caused by hyperexcitable stretch reflexes, appearing in up to 40% of stroke survivors within the first year. Before any intervention, clinicians must quantify which muscles are overactive and how severely, using standardized passive-stretch testing that guides every downstream treatment decision.
The MAS grades resistance felt when an examiner passively moves a joint through its range of motion:
• 0 — No increase in muscle tone • 1 — Slight increase, a catch and release, or minimal resistance at end of range • 1+ — Slight increase, catch followed by minimal resistance through less than half of range • 2 — More marked increase through most of the range, but joint moves easily • 3 — Considerable increase, passive movement difficult • 4 — Affected part rigid in flexion or extension
Because spasticity is velocity-dependent, the same joint may feel near-normal when moved slowly and dramatically stiff when moved quickly — this dependency is itself diagnostic of an upper motor neuron lesion rather than fixed (myostatic) contracture.
Spasticity distribution after stroke follows recognizable synergy patterns driven by loss of descending corticoreticulospinal inhibition:
• Upper limb: shoulder adduction/internal rotation, elbow flexion (biceps, brachialis), forearm pronation, wrist and finger flexion, thumb-in-palm — the classic "flexed arm" posture • Lower limb: hip adduction (scissoring), knee extension or flexion, ankle plantarflexion with inversion (equinovarus) — producing a stiff-legged, circumducted gait
Identifying which specific muscles drive the pattern — rather than treating the limb as a whole — is what allows botulinum toxin to be targeted precisely instead of diffusely weakening the limb.
Spasticity assessment is repeated at every visit: MAS score, passive/active range of motion, and functional impact (pain, hygiene, dressing, gait) together decide whether — and where — to inject, not tone alone.
Surface anatomy alone is unreliable for small or deep muscles, and inaccurate placement wastes toxin and risks weakening the wrong structure. Electromyography (EMG) and ultrasound guidance confirm the needle tip sits inside the intended, electrically overactive muscle before a single unit is injected.
Two muscles can look identical on the surface yet only one drives the abnormal posture. EMG listens for spontaneous or stretch-evoked motor unit activity through the injection needle itself — a hyperactive, crackling signal confirms the needle sits in an electrically overactive muscle, while a silent muscle is likely a passive, secondarily shortened bystander that toxin would not help.
Real-time ultrasound visualizes muscle fascicle orientation, thickness, depth, and adjacent neurovascular structures, letting the injector avoid vessels/nerves and place toxin near the motor endplate band where uptake is fastest. Ultrasound is especially valuable for small, deep, or overlapping forearm and calf muscles (e.g., flexor digitorum profundus vs. superficialis, tibialis posterior) where palpation cannot reliably distinguish layers.
Combining EMG confirmation with ultrasound visualization is now considered best practice: ultrasound answers "am I in the right muscle, at the right depth," while EMG answers "is this muscle actually overactive."
Botulinum neurotoxin type A (BoNT-A) is one of the most potent biological toxins known, yet therapeutically it is exquisitely local: injected into a target muscle, it produces temporary, reversible chemodenervation confined to the treated fibers by silencing the molecular machinery that releases acetylcholine.
1. Binding: the toxin heavy chain binds SV2 and polysialoganglioside receptors specific to cholinergic nerve terminals, concentrating uptake at neuromuscular junctions.
2. Internalization: the terminal is triggered to endocytose the toxin into a synaptic vesicle; low pH inside the endosome drives the heavy chain to form a channel and translocate the light chain into the cytosol.
3. Cleavage: the light chain is a zinc-dependent endopeptidase that cleaves SNAP-25, a core component of the SNARE complex (SNAP-25 + syntaxin + synaptobrevin) that normally zippers acetylcholine vesicles to the presynaptic membrane for fusion.
With SNAP-25 severed, vesicles carrying acetylcholine can no longer dock and fuse with the presynaptic membrane. Acetylcholine is not released into the synaptic cleft, nicotinic receptors on the muscle end-plate are not activated, and the muscle fiber fails to depolarize and contract — a temporary, focal chemodenervation. Because only the injected fibers are affected, adjacent non-injected muscles keep functioning normally.
Recovery occurs through nerve terminal sprouting and eventual regeneration of functional SNARE machinery in the original terminal — which is why the effect is reversible and re-injection is needed roughly every 3–4 months.
Botulinum toxin does not act instantly, and its effect is not permanent. Understanding the shape of the time-response curve — a lag phase, a rise to peak, a plateau, and a gradual decline — is essential for setting patient expectations, timing follow-up assessments, and scheduling adjunct therapies.
Pre-onset (day 0–3): enzymatic cleavage of SNAP-25 is already underway intracellularly, but clinically the muscle still behaves as before — existing vesicle pools keep transmission going briefly.
Building effect (day 3–~21): as releasable vesicle stores are progressively depleted at blocked terminals, tone measurably falls; patients often first notice easier hand-opening or foot clearance in this window.
Peak effect (~week 3–6): maximal chemodenervation. This is the optimal window for serial casting, splint fitting, botulinum-toxin-assisted stretching, and intensive task-specific therapy, while resistance is lowest.
Waning (week 6 onward, back toward baseline by ~12–16 weeks): nerve terminal sprouting and SNARE protein turnover restore transmission gradually; tone drifts back toward pre-injection levels, and a re-injection decision is made — never sooner than ~12 weeks, both because effect is still present and to reduce the risk of neutralizing antibody formation.
Re-injecting too early — chasing residual spasticity before the previous dose has fully worn off — increases cumulative toxin exposure and the risk of developing neutralizing antibodies against BoNT-A, which can cause secondary treatment failure. Spacing injections at least 12 weeks apart, and using the lowest effective dose, preserves long-term responsiveness across years of repeated treatment cycles.
The time-response curve is why outcome must always be judged relative to days-since-injection: the same muscle can score MAS 3 on day 1, MAS 1 at week 4, and MAS 2–3 again by week 14 — none of these readings alone tells the full story.
Lower muscle tone is a means, not an end. The real goal of spasticity management is functional: easier hygiene and dressing, less pain, better limb positioning, and — when the pattern allows — improved active use of the limb. Botulinum toxin achieves its best outcomes when paired deliberately with rehabilitation delivered during the peak-effect window.
For a severely affected, non-functional hand, goals are often passive: preventing skin maceration and contracture in the palm, easing glove/splint donning, reducing pain from a clenched fist. For a more mildly affected limb with retained voluntary movement, goals become active: improved grasp/release for reaching tasks, or better toe clearance and reduced circumduction during gait. Goal-setting before treatment (often with tools like Goal Attainment Scaling) keeps the injection plan tied to what actually matters to the patient.
Botulinum toxin creates a temporary window of reduced resistance — it does not by itself lengthen a shortened muscle or retrain movement. During the peak-effect weeks, clinicians layer on:
• Serial casting or dynamic/static splinting to gain passive range and prevent contracture • Prolonged stretching and positioning programs • Task-specific, repetitive active practice for muscles with retained voluntary control • Electrical stimulation or constraint-induced movement therapy in selected patients
Combined toxin-plus-therapy protocols consistently outperform toxin alone for range-of-motion and functional outcomes, because the biomechanical opportunity created by chemodenervation is actively consolidated into a durable change rather than being left to passively fade.
Re-assessment before each re-injection cycle asks three questions: has tone returned toward baseline, has function/pain changed, and have goals shifted — the treatment plan for cycle two is rarely identical to cycle one.